SCHEMBL2178546

SCHEMBL2178546

CC(C)C(C(=O)O)N1Cc2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc2C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.54
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDR P35968 4/20 0.47
CSGALNACT1 Q8TDX6 1/20 0.47
THRB P10828 1/20 0.47
TP53 P04637 1/20 0.46
NTRK1 P04629 2/20 0.44
NTRK2 Q16620 2/20 0.44
AURKB Q96GD4 2/20 0.44
PLK4 O00444 1/20 0.44
AURKA O14965 1/20 0.44
ROCK2 O75116 1/20 0.44
CHEK2 O96017 1/20 0.44
EGFR P00533 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2182706 1.00 DGAT1 (0.54) DGAT1MEN1MAPTHTTRAB9A
SCHEMBL2178541 1.00 DGAT1 (0.54) DGAT1MEN1MAPTHTTRAB9A
SCHEMBL2178008 0.93 DGAT1 (0.49) DGAT1MAPTHTTKDM4ESMN1; SMN2
SCHEMBL2181755 0.93 DGAT1 (0.49) DGAT1MAPTHTTKDM4ESMN1; SMN2
SCHEMBL2179431 0.93 KDR (0.52) DGAT1MEN1MAPTHTTRAB9A
SCHEMBL2178373 0.93 KDR (0.52) DGAT1MEN1MAPTHTTRAB9A
SCHEMBL2178379 0.93 KDR (0.52) DGAT1MEN1MAPTHTTRAB9A
SCHEMBL2178363 0.92 DGAT1 (0.49) DGAT1CSGALNACT1TP53
SCHEMBL2178359 0.92 DGAT1 (0.49) DGAT1CSGALNACT1TP53
SCHEMBL2180531 0.91 DGAT1 (0.56) DGAT1MEN1MAPTHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885MEN1 3071/4885MAPT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.